Moleculin Biotech

+$0.07 (+4.86%) Today
+$0.02 (+1.32%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MBRX and other ETFs, options, and stocks.

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML.

CEO
Walter V. Klemp
Employees
21
Headquarters
Houston, Texas
Founded
2015

MBRX Key Statistics

Market cap
43.15M
Price-Earnings ratio
—
Dividend yield
—
Average volume
57.48K
High today
$1.54
Low today
$1.41
Open price
$1.44
Volume
67.22K
52 Week high
$3.99
52 Week low
$1.02

MBRX News

BenzingaMay 26

Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122

Moleculin Biotech, Inc. MBRX announced dosing of subjects in its Phase 1a clinical study of WP1122 in healthy volunteers for the treatment of COVID-19. The fir

MBRX Earnings

-$0.36
-$0.24
-$0.12
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 10, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure